Judit SIMON is Professor of Health Economics, Head of the Department of Health Economics, Deputy Head of the Center for Public Health and Coordinator of the Public Health Doctoral programme at the Medical University of Vienna. She is Visiting Professor at the University of Oxford and Corvinus University Budapest. She had previous appointments at UCL, LSE and the University of Oxford in the UK. She holds an MD, a BSc in Economics and a BA in Medical Translation (University of Szeged), an MSc in Health Economics (University of York), and a DPhil in Public Health/Health Economics (University of Oxford). She is Fellow through Distinction of the UK Faculty of Public Health (FFPH).
Her main expertise include applied and methodological (mental) health economic evaluation research alongside clinical studies/guidelines/HTAs, evidence synthesis and health services and systems research. She has been PI/Co-I on 22 grants with over 37 million Euros funding (EC, ECNP, FWF, LBG, NIHR, WHO, WWTF) in the fields of mental health, public health, nutrition, cancer and palliative care economics. Most recently, she has led European research on improving (mental) health economic evaluation methods (PECUNIA), the physical comorbidity costs of mental disorders (ECNP), the cost-effectiveness of palliative/end-of-life care (iLIVE) and the value of family-intervention for adolescent mental health promotion in Eastern Europe (FLOURISH), as well as acted as advisor to the EBC Value of Treatment project. She has over 160 publications, and is senior editor at BMJ Mental Health, BJPsych Open and Bipolar Disorders.
Latest grants (PI/co-I):
- STREAMLINE: Establishing a Reference Unit Costs catalogue for the optimized evaluation and planning of mental healthcare in Vienna (WWTF, 2023-2025)
- VABABS: Improvement and protection of women’s health at a population level by Value Based Breast Screening in Vienna (WWTF, 2023-2027)
- FLOURISH (EC Horizon Europe, 2023-2026)
- ASCEnD: Aripiprazole/ sertraline combination: Clinical and cost-effectiveness in comparison with quetiapine for the treatment of bipolar depression. An open label randomised controlled trial (UK NIHR HTA, 2022-2026)
- PallPROMs: Validating a core set of patient-reported outcome measures (PROMS) to monitor and evaluate quality of palliative care in Austria (FWF, 2021-2023)
- PerMedSchiz: Personalised medicine in schizophrenia (EC H2020 ERAPerMed/FWF, 2020-2025)
- The iLIVE project: Living well, dying well. A research programme to support living until the end (EC H2020 RIA, 2019-2023)
- PAX-D: Pramipexole for treatment resistant major depression (UK NIHR EME, 2019-2024)
- PAX-BD: Pramipexole for treatment resistant bipolar depression (UK NIHR HTA, 2018-2023)
- The excess physical co-morbidity costs of mental disorders (ECNP, 2018-2022)
- PECUNIA: ProgrammE in Costing, resource use measurement and outcome valuation for Use in multi-sectoral National and International health economic evaluAtions (EC H2020 RIA, 2018-2021)
- LBI AD: Ludwig Boltzmann Institute for Applied Diagnostics (LBG, 2016-2023)